Close

Japan To Make Its Preparedness & Response To Pandemic Robust

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

The Coalition For Epidemic Preparedness Innovation in Norway and the Strategic Centre of Biomedical Advanced Vaccine Research and Development for Preparedness and Response have gone on to sign a Memorandum of Cooperation- MoC so as to strengthen the partnership between both organisations as they look forward to speeding up global preparedness as well as response to any future pandemics.

Both CEPI and SCARDA have shared missions when it comes to funding the development of vaccines against diseases that are infectious and hence this new collaboration is going to assist the organisations in sharing expertise, experience, as well as knowledge and partner on the work areas that help contribute to the goals when it comes to both organisations.

It is well to be noted that by way of both partnerships, both organisations will be able to share information and insights on vaccine development, health security, manufacturing, and other themes that concern the preparedness of pandemics and epidemics. The partners will go ahead with a collaboration in terms of vaccine development in the case of priority pathogens as well as priority virus families of mutual interest, enabling them to select as well as focus when it comes to c complementary projects as well as investments sans duplicating the effort or even the resources.

CEPI and SCARDA will also look to coordinate on functions that go on to support the 100-Days mission, which happens to be embraced by the G7 as well as the G20 and which looks to speed up the time taken to create safe, effective, and accessible vaccines when it comes to emerging diseases having pandemic potential to 100 days.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back